Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis
- 1 February 2020
- journal article
- review article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 26 (2) , 189-198
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMTBone Marrow Transplantation, 2010
- Antiviral prophylaxis in haematological patients: Systematic review and meta-analysisEuropean Journal of Cancer, 2009
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging studyBlood, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal TransplantationAmerican Journal of Transplantation, 2008
- Cytomegalovirus Pneumonia in Adults with Leukemia: An Emerging ProblemClinical Infectious Diseases, 2001
- Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantationJournal of Antimicrobial Chemotherapy, 1985
- Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial.BMJ, 1983
- Acyclovir Prophylaxis of Herpes-Simplex-Virus InfectionsNew England Journal of Medicine, 1981